CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute...
Phase 3
Budapest, Hungary and 108 other locations
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...
Phase 3
Budapest, Hungary and 160 other locations
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible f...
Phase 3
Budapest, Hungary and 171 other locations
available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second ...
Phase 3
Budapest, Hungary and 72 other locations
Some people with MDS have a risk of the disease progressing to acute myeloid leukemia (AML), and a risk of death ...
Phase 3
Szekesfehervar, Fejer, Hungary and 221 other locations
This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a...
Phase 4
Budapest, Hungary and 96 other locations
Clinical trials
Research sites
Resources
Legal